EUVIMEDEUVIMED entdecken
Crossref

Antiviral peptides inhibiting the main protease of SARS‐CoV‐2 investigated by computational screening and in vitro protease assay

James Stewart, Jakaria Shawon, Md Ackas Ali iD, Blaise Williams, A D A Shahinuzzaman, Sharmin Akther Rupa, Taha Al-Adhami, Ruoqing Jia iD, Cole Bourque, Ryan Faddis, Kaylee Stone, Md Abu Sufian und 4 weitere

Journal of Peptide Science · 2024-04 · 30 (4)

DOI: 10.1002/psc.3553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Peptide Science, online erschienen am 29.11.2023. Verfasst von James Stewart und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Kennesaw State University, Kennesaw, GA, USA. Hauptthemen laut MEDLINE: Peptide Hydrolases, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: Kennesaw State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) plays an important role in viral replication and transcription and received great attention as a vital target for drug/peptide development. Therapeutic agents such as small‐molecule drugs or peptides that interact with the Cys–His present in the catalytic site of Mpro are an efficient way to inhibit the protease. Although several emergency‐approved vaccines showed good efficacy and drastically dropped the infection rate, evolving variants are still infecting and killing millions of people globally. While a small‐molecule drug (Paxlovid) received emergency approval, small‐molecule drugs have low target specificity and higher toxicity. Besides small‐molecule drugs, peptide therapeutics are thus gaining increasing popularity as they are easy to synthesize and highly selective and have limited side effects. In this study, we investigated the therapeutic value of 67 peptides targeting Mpro using molecular docking. Subsequently, molecular dynamics (MD) simulations were implemented on eight protein–peptide complexes to obtain molecular‐level information on the interaction between these peptides and the Mpro active site, which revealed that temporin L, indolicidin, and lymphocytic choriomeningitis virus (LCMV) GP1 are the best candidates in terms of stability, interaction, and structural compactness. These peptides were synthesized using the solid‐phase peptide synthesis protocol, purified by reversed‐phase high‐performance liquid chromatography (RP‐HPLC), and authenticated by mass spectrometry (MS). The in vitro fluorometric Mpro activity assay was used to validate the computational results, where temporin L and indolicidin were observed to be very active against SARS‐CoV‐2 Mpro with IC 50 values of 38.80 and 87.23 μM, respectively. A liquid chromatography–MS (LC–MS) assay was developed, and the IC 50 value of temporin L was measured at 23.8 μM. The solution‐state nuclear magnetic resonance (NMR) structure of temporin L was determined in the absence of sodium dodecyl sulfate (SDS) micelles and was compared to previous temporin structures. This combined investigation provides critical insights and assists us to further develop peptide inhibitors of SARS‐CoV‐2 Mpro through structural guided investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptide HydrolasesCOVID-19HumansSARS-CoV-2Molecular Docking SimulationAntiviral AgentsProtease InhibitorsMolecular Dynamics Simulation

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antiviral peptidesmain proteasemolecular dynamics simulationpeptide inhibitor

Substanzen

Peptide HydrolasesAntiviral AgentsProtease Inhibitors

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, Kennesaw State University, Kennesaw, GA, USA.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Division of Infectious Diseases and Division of Computer-Aided Drug Design, The Red-Green Research Centre, BICCB, Tejgaon, Dhaka, Bangladesh.
  • Pharmaceutical Sciences Research Division, Bangladesh Council of Scientific and Industrial Research (BCSIR), Dhaka, Bangladesh.
  • Department of Chemistry, Comilla University, Cumilla, Bangladesh.
  • Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, London, UK.

ORCID-Profile: Md Ackas Ali, Ruoqing Jia, Andrew C McShan, Mohammad A Halim

Förderung

  • Kennesaw State University

Zitieren

APA

Stewart, J., Shawon, J., Ali, M. A., Williams, B., Shahinuzzaman, A. D. A., Rupa, S. A., Al-Adhami, T., Jia, R., Bourque, C., Faddis, R., Stone, K., Sufian, M. A., Islam, R., McShan, A. C., Rahman, K. M., & Halim, M. A. (2024). Antiviral peptides inhibiting the main protease of SARS‐CoV‐2 investigated by computational screening and in vitro protease assay. Journal of Peptide Science, 30(4). https://doi.org/10.1002/psc.3553

Vancouver

Stewart J, Shawon J, Ali MA, Williams B, Shahinuzzaman ADA, Rupa SA, et al. Antiviral peptides inhibiting the main protease of SARS‐CoV‐2 investigated by computational screening and in vitro protease assay. Journal of Peptide Science. 2024;30(4). doi:10.1002/psc.3553

BibTeX
@article{Stewart2024,
  author = {Stewart, James and Shawon, Jakaria and Ali, Md Ackas and Williams, Blaise and Shahinuzzaman, A D A and Rupa, Sharmin Akther and Al-Adhami, Taha and Jia, Ruoqing and Bourque, Cole and Faddis, Ryan and Stone, Kaylee and Sufian, Md Abu and Islam, Rajib and McShan, Andrew C and Rahman, Khondaker Miraz and Halim, Mohammad A},
  title = {Antiviral peptides inhibiting the main protease of SARS‐CoV‐2 investigated by computational screening and in vitro protease assay},
  journal = {Journal of Peptide Science},
  year = {2024},
  volume = {30},
  number = {4},
  doi = {10.1002/psc.3553}
}
Kostenlos starten →